OraSure Technologies (OSUR) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue reached $54.3 million, near the top of guidance, with core revenue at $35.4 million and sequential improvement from new product launches.

• Fulfilled the largest U.S. government COVID-19 contract, contributing $18.9 million, as COVID-19 diagnostics revenue fell 60% year-over-year.

• Achieved WHO prequalification for the OraQuick HCV self-test, the first hepatitis C self-test to receive this designation.

• Launched new FDA-cleared packaging for the OraQuick HIV self-test, improving shipping efficiency and expanding access.

• Expanded partnerships in oncology and genetic testing, including agreements with Exact Sciences, Variantyx, and new saliva-based liquid biopsy collaborations.

Financial highlights

• Q2 2024 net revenues: $54.3 million, down 36% year-over-year; core revenues declined 7%, COVID-19 revenues fell 60%.

• GAAP gross margin improved to 45.4% from 30.9% year-over-year; non-GAAP gross margin was 47.4%.

• GAAP operating loss was $2.7 million, improved from $6.4 million last year; non-GAAP operating income was $3.3 million.

• Q2 2024 EPS: $(0.01) GAAP, $0.07 non-GAAP.

• Cash, cash equivalents, and short-term investments totaled $267.4 million at quarter-end; Q2 operating cash flow was $7.8 million.

Outlook and guidance

• Q3 2024 revenue guidance: $37–$41 million, with core revenues of $36–$39 million and InteliSwab revenues of $1–$2 million.

• Q3 gross margin expected in the low 40% range, returning to mid-40% in Q4; long-term target is 50%.

• Management expects further core revenue progress in Q3 and aims for break-even operating cash flow from core business by year-end.

• International diagnostics expected to drive most of the sequential revenue increase in Q3.

• Existing cash and equivalents are expected to fund operations and capital expenditures over the next twelve months.